GENTICEL has a total of 34 patent applications. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are MOMOTARO GENE INC, REALTA HOLDINGS LLC and SAIBA GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Canada | 3 | |
#4 | China | 3 | |
#5 | Republic of Korea | 3 | |
#6 | Mexico | 3 | |
#7 | United States | 3 | |
#8 | Brazil | 2 | |
#9 | Hong Kong | 2 | |
#10 | Japan | 2 | |
#11 | Australia | 1 | |
#12 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides | |
#5 | Enzymes | |
#6 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Misseri Yolande | 24 |
#2 | Goubier Anne | 15 |
#3 | Esquerre Michael | 10 |
#4 | Bridonneau Philippe | 8 |
#5 | Joly Etienne | 8 |
#6 | Momot Marie | 7 |
#7 | Yolande Misseri | 6 |
#8 | Timmerman Benedikt | 4 |
#9 | Equerre Michael | 4 |
#10 | Etienne Joly | 3 |
Publication | Filing date | Title |
---|---|---|
EP3342421A1 | Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response | |
EP3037103A1 | Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV | |
EP2690172A1 | CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses | |
EP2689786A1 | HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders | |
EP2478915A1 | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses | |
TW200817036A | Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |